Related Experiment Videos
Sophisticated primary and secondary atherosclerosis prevention is cost effective
1Lawrence Berkeley Laboratory, University of California, Berkeley Lipid Institute, Sequoia Hospital, Redwood City 94062-2799, USA.
Insights
Lipoprotein therapy significantly reduces cardiovascular events and procedures. This translates to substantial cost savings, potentially over $1 billion annually for U.S. coronary artery disease patients.
Area of Science:
- Cardiovascular Medicine
- Health Economics
Background:
- Large clinical trials demonstrate the efficacy of lipoprotein therapy in reducing cardiovascular events.
- Cardiovascular events and procedures represent a significant healthcare cost burden.
Purpose of the Study:
- To evaluate the cost-effectiveness of lipoprotein therapy in managing cardiovascular disease.
- To estimate potential healthcare cost savings associated with widespread adoption of lipoprotein therapy.
Main Methods:
- Analysis of data from large clinical trials focusing on lipoprotein therapy.
- Comparison of treatment costs versus cost savings from reduced cardiovascular events and procedures.
- Extrapolation of findings to the U.S. population with coronary artery disease (CAD).
Main Results:
- Clinical end-point trials showed average cost savings of approximately $1,500/patient/year.
- Arteriographic trials indicated a wide range of cost implications, from $2,273/patient/year cost to -$901/patient/year savings.
- Potential annual savings for U.S. CAD patients estimated to exceed $1 billion.
Conclusions:
- Lipoprotein therapy offers significant clinical benefits and potential for substantial healthcare cost savings.
- Optimizing lipoprotein therapy could lead to considerable economic advantages in managing coronary artery disease.
- Widespread effective treatment of CAD patients could yield national economic benefits exceeding $1 billion annually.
Abstract:
Large clinical trials involving lipoprotein therapy and clinical end-points or arteriographic change have demonstrated a significant reduction in cardiovascular events and the need for cardiovascular procedures. Clinical end-point trials that used relatively weak treatment modalities have resulted in reduced clinical events and when the cost savings of the reduced number of events is balanced against the cost of treatment, the average difference is approximately US$1,500/patient/year. Arteriographic trials have used similar or more aggressive lipoprotein therapy over shorter periods of time. Similar estimates of cost savings from reduced clinical events balanced against the cost of treatment indicates a wide spectrum of estimated patient costs. These estimates range between a cost of $2,273/patient/year, to a cost savings of -$901/patient/year. Extrapolation to the United States population with coronary artery disease (CAD) suggests that greater than $1 billion per year could be saved if CAD patients received similar treatment and responded in a similar manner.